Stifel Nicolaus Begins Coverage on Beta Bionics (NASDAQ:BBNX)

Research analysts at Stifel Nicolaus began coverage on shares of Beta Bionics (NASDAQ:BBNX) in a note issued to investors on Monday, Marketbeat reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. Stifel Nicolaus’ target price suggests a potential upside of 30.41% from the stock’s current price.

BBNX has been the subject of a number of other research reports. Robert W. Baird initiated coverage on Beta Bionics in a report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 target price for the company. Leerink Partners started coverage on Beta Bionics in a report on Monday. They issued an “outperform” rating and a $28.00 price objective for the company. LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price on the stock. Baird R W upgraded shares of Beta Bionics to a “hold” rating in a research note on Thursday, February 20th. Finally, Piper Sandler began coverage on shares of Beta Bionics in a research report on Monday. They issued an “overweight” rating and a $26.00 target price for the company. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Beta Bionics currently has an average rating of “Moderate Buy” and a consensus price target of $24.83.

Beta Bionics Trading Down 6.9 %

Shares of BBNX opened at $19.17 on Monday. Beta Bionics has a twelve month low of $19.08 and a twelve month high of $24.50.

Insider Transactions at Beta Bionics

In related news, insider Mike Mensinger purchased 33,350 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the transaction, the insider now directly owns 59,019 shares in the company, valued at $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the transaction, the insider now directly owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.